EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A Comprehensive Mutational and Histopathological Analysis of STK11-Mutant Non–Small Cell Lung Carcinomas

Cristiana M Pineda, Zoe Guan, Hyunwoo Kwon, Deepa Rangachari, Daniel B Costa, Paul A VanderLaan

Modern Pathology · 2026-01 · 39 (1) · 100938

DOI: 10.1016/j.modpat.2025.100938 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Modern Pathology, 2026-01. Verfasst von Cristiana M Pineda und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Protein Serine-Threonine Kinases. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, National Institutes of Health National Cancer Institute, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Despite recent advances in the understanding of genomic and immunopathological mechanisms of lung cancer, this disease remains the leading cause of cancer-related deaths in the United States. STK11 (LKB1) mutations are present in approximately 20% of non-small cell lung cancers (NSCLCs) and drive tumor progression through disruption of cellular metabolism, polarity, and stress responses, ultimately leading to immune evasion and resistance to cancer therapy. Although these tumors are associated with poor prognoses, the clinicopathological significance of different STK11 mutation subtypes and their associations with tumor histology, cellular behavior, metastatic potential, and clinical outcomes remain incompletely understood. In this study, we retrospectively analyzed a large cohort of STK11-mutant and STK11 wild-type NSCLCs using a combination of next-generation sequencing, immunologic biomarkers, histopathological characterization, and radiographic imaging. Overall, we demonstrate that STK11-mutant tumors display diverse molecular and morphologic features and are associated with high rates of aggressive histopathological growth patterns, lymphovascular invasion, and spread through the airspaces. Among stage 4 cases, STK11 mutations had notable differences in organotropism, with the STK11-loss cohort in particular demonstrating the highest rates of brain metastases at the time of initial diagnosis. Furthermore, among stage 4 cases, whereas all STK11 mutation types resulted in decreased overall survival probability compared with the STK11 wild-type cohort, the effect appeared most pronounced among the STK11-loss/KRAS-mutant group. These findings underscore the heterogeneity of STK11-mutant NSCLCs and highlight the opportunity for further investigation into specific STK11 mutation subtypes in guiding prognosis and therapeutic decision-making for individuals with lung cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsProtein Serine-Threonine KinasesHumansAMP-Activated Protein Kinase KinasesFemaleMaleMutationMiddle AgedAgedRetrospective StudiesBiomarkers, TumorDNA Mutational AnalysisAdultAged, 80 and over

Stichwörter der Autor:innen

STK11cancer genomicscomutational profilenext-generation sequencingnon–small cell lung cancer

Substanzen

STK11 protein, humanProtein Serine-Threonine KinasesAMP-Activated Protein Kinase KinasesBiomarkers, Tumor

Autor:innen und Institutionen

  • Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts.
  • Department of Biostatistics, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.
  • Department of Medicine, Division of Medical Oncology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts.
  • Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts. Electronic address: pvanderl@bidmc.harvard.edu.

Förderung

  • NCI NIH HHS
  • National Institutes of Health National Cancer Institute
  • National Institutes of Health

Zitieren

APA

Pineda, C. M., Guan, Z., Kwon, H., Rangachari, D., Costa, D. B., & VanderLaan, P. A. (2026). A Comprehensive Mutational and Histopathological Analysis of STK11-Mutant Non–Small Cell Lung Carcinomas. Modern Pathology, 39(1), 100938. https://doi.org/10.1016/j.modpat.2025.100938

Vancouver

Pineda CM, Guan Z, Kwon H, Rangachari D, Costa DB, VanderLaan PA. A Comprehensive Mutational and Histopathological Analysis of STK11-Mutant Non–Small Cell Lung Carcinomas. Modern Pathology. 2026;39(1):100938. doi:10.1016/j.modpat.2025.100938

BibTeX
@article{Pineda2026,
  author = {Pineda, Cristiana M and Guan, Zoe and Kwon, Hyunwoo and Rangachari, Deepa and Costa, Daniel B and VanderLaan, Paul A},
  title = {A Comprehensive Mutational and Histopathological Analysis of STK11-Mutant Non–Small Cell Lung Carcinomas},
  journal = {Modern Pathology},
  year = {2026},
  volume = {39},
  number = {1},
  pages = {100938},
  doi = {10.1016/j.modpat.2025.100938}
}
Kostenlos starten →